PTJ
TPST icon

Paul Tudor Jones’s Tempest Therapeutics TPST Stock Holding History

Paul Tudor Jones’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-45
Closed -$249K – 1376
2017
Q1 		$249K Sell
45
-71
-61% -$331K 0.01% 1109
2016
Q4 		$519K Buy
116
+106
+1,060% +$1.32M 0.01% 702
2016
Q3 		$210K Sell
10
-5
-33% -$90.5K ﹤0.01% 1231
2016
Q2 		$224K Buy
+15
New +$343K ﹤0.01% 1347

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Paul Tudor Jones's TPST Position: Q2 2017 in Review

Paul Tudor Jones sold out of Tempest Therapeutics (TPST) in Q2 2017, closing a stake of 45 shares — an estimated $249K sold.

Paul Tudor Jones first reported a position in TPST in Q2 2016 and held it in 4 quarters. The position peaked at $519K in Q4 2016. 54 funds tracked by Wall St. Rank hold TPST as of Q2 2017.

  • Paul Tudor Jones reported no remaining Tempest Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Paul Tudor Jones sold 45 Tempest Therapeutics shares in Q2 2017, an estimated $249K.
  • Paul Tudor Jones first reported a position in Tempest Therapeutics in Q2 2016 and held it in 4 quarters.
  • Paul Tudor Jones's Tempest Therapeutics position peaked at $519K in Q4 2016.
  • 54 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2017.

Based on Tudor Investment Corp's 13F filing for Q2 2017, filed 14 Aug 2017.